Scientific article

Update on multiple sclerosis treatments

Published inSchweizerische medizinische Wochenschrift, vol. 144, w14012
Publication date2014

Relapsing-remitting multiple sclerosis (RRMS) management has dramatically changed over the past decade. New drugs have arrived on the market, allowing for more individualised treatment selection. However, this diversity has increased the complexity of RRMS patient follow-up. In this review, we provide summarised information about treatment efficacy, potential side-effects, follow-up recommendations, vaccinations, and pregnancy safety issues for all currently available disease modifying therapies and those awaiting approval.

  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Crotonates/therapeutic use
  • Dimethyl Fumarate
  • Fingolimod Hydrochloride
  • Fumarates/therapeutic use
  • Humans
  • Immunoglobulin G/therapeutic use
  • Immunosuppressive Agents/administration & dosage/adverse effects/therapeutic use
  • Interferon-beta/therapeutic use
  • Multiple Sclerosis, Relapsing-Remitting/drug therapy
  • Natalizumab
  • Propylene Glycols/therapeutic use
  • Sphingosine/analogs & derivatives/therapeutic use
  • Toluidines/therapeutic use
Citation (ISO format)
BRIDEL, Claire, LALIVE D’EPINAY, Patrice. Update on multiple sclerosis treatments. In: Schweizerische medizinische Wochenschrift, 2014, vol. 144, p. w14012. doi: 10.4414/smw.2014.14012
Main files (1)
Article (Published version)
ISSN of the journal0036-7672

Technical informations

Creation11/30/2016 3:05:00 PM
First validation11/30/2016 3:05:00 PM
Update time03/15/2023 1:05:52 AM
Status update03/15/2023 1:05:52 AM
Last indexation05/02/2024 6:00:29 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack